BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:COVID-19 readouts · AssetMemo
X-WR-CALDESC:Upcoming phase 1/2 and later readouts in COVID-19\, from Clini
 calTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04363853-6083@assetmemo.bio
DTSTAMP:20261121T005419Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Actemra / RoActemra (tocilizumab): Phase 2 readout est. (NCT0436385
 3)
DESCRIPTION:Actemra / RoActemra (tocilizumab)\, phase 2\, COVID-19.\nStudy:
  Tocilizumab Treatment in Patients With COVID-19\nEstimated primary comple
 tion: 1 December 2026. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/tocilizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT04363853
URL:https://assetmemo.bio/drug/tocilizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07013474-11275@assetmemo.bio
DTSTAMP:20261121T005419Z
DTSTART;VALUE=DATE:20270928
DTEND;VALUE=DATE:20270929
SUMMARY:Ibuzatrelvir: Phase 3 readout est. (NCT07013474)
DESCRIPTION:Ibuzatrelvir\, phase 3\, COVID-19.\nStudy: A Study to Learn Abo
 ut the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severel
 y Immunocompromised\nEstimated primary completion: 28 September 2027. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/ibuzatrelvir#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07013474
URL:https://assetmemo.bio/drug/ibuzatrelvir#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06679140-11275@assetmemo.bio
DTSTAMP:20261121T005419Z
DTSTART;VALUE=DATE:20271001
DTEND;VALUE=DATE:20271002
SUMMARY:Ibuzatrelvir: Phase 3 readout est. (NCT06679140)
DESCRIPTION:Ibuzatrelvir\, phase 3\, COVID-19.\nStudy: A Study to Learn Abo
 ut a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients W
 ith COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease\n
 Estimated primary completion: 1 October 2027. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/ibuzatrelvir#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT06679140
URL:https://assetmemo.bio/drug/ibuzatrelvir#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02735707-98@assetmemo.bio
DTSTAMP:20261121T005419Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Olumiant (baricitinib): Phase 3 readout est. (NCT02735707)
DESCRIPTION:Olumiant (baricitinib)\, phase 3\, COVID-19.\nStudy: Randomized
 \, Embedded\, Multifactorial Adaptive Platform Trial for Community- Acquir
 ed Pneumonia\nEstimated primary completion: June 2028. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/baricitinib#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT02735707
URL:https://assetmemo.bio/drug/baricitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02735707-6083@assetmemo.bio
DTSTAMP:20261121T005419Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Actemra / RoActemra (tocilizumab): Phase 3 readout est. (NCT0273570
 7)
DESCRIPTION:Actemra / RoActemra (tocilizumab)\, phase 3\, COVID-19.\nStudy:
  Randomized\, Embedded\, Multifactorial Adaptive Platform Trial for Commun
 ity- Acquired Pneumonia\nEstimated primary completion: June 2028. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/tocilizumab#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT02735707
URL:https://assetmemo.bio/drug/tocilizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04381936-98@assetmemo.bio
DTSTAMP:20261121T005419Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Olumiant (baricitinib): Phase 3 readout est. (NCT04381936)
DESCRIPTION:Olumiant (baricitinib)\, phase 3\, COVID-19.\nStudy: Randomised
  Evaluation of COVID-19 Therapy\nEstimated primary completion: 30 Septembe
 r 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/baricitinib#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT04381
 936
URL:https://assetmemo.bio/drug/baricitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04381936-6083@assetmemo.bio
DTSTAMP:20261121T005419Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Actemra / RoActemra (tocilizumab): Phase 3 readout est. (NCT0438193
 6)
DESCRIPTION:Actemra / RoActemra (tocilizumab)\, phase 3\, COVID-19.\nStudy:
  Randomised Evaluation of COVID-19 Therapy\nEstimated primary completion: 
 30 September 2028. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/to
 cilizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT04381936
URL:https://assetmemo.bio/drug/tocilizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
